Skip to main content
. 2021 May 15;904:174196. doi: 10.1016/j.ejphar.2021.174196

Fig. 3.

Fig. 3

Role of the Cys-LTR antagonist montelukast in the mitigation of extrapulmonary manifestations in Covid-19.